



Medicamen Biotech Limited

Q4 FY22


Investor Presentation

KEY HIGHLIGHTS

- ❖ *CDMO agreement with a European Company*
- ❖ *Launched 12 Oncology products in Domestic Market*
- ❖ *Tech transfer for another 7 products for Domestic Market*
- ❖ *R&D developments of products in full swing which are going to be off patented in next 5 years.*
- ❖ *Our prime focus is to reach quality oncology products to cancer patients in India for which we are committed to make it available in all the leading government and private cancer care centres!*

Financial Highlights Y-o-Y Performance

Medicamen Biotech Limited posts yearly results with a steady revenue growth of 4.81 % YoY



UNIQUE VALUE PROPOSITIONS



Differentiated Dosage Forms In Oncology

Expertise:-

- ❖ TKI's
- ❖ NDDS
- ❖ RTUs
- ❖ Extended release



Reverse Integration

- ❖ MBL develops APIs 100% of its own formulations
- ❖ Tech transfer R&D to API to formulation



Robust Product Pipeline

- ❖ Launched 12 products
- ❖ To be launched soon 7 products



Diversified product mix

- ❖ Oncology- Breast cancer, Brain Tumor, Renal Cancer, Prostate Cancer ETC.
- ❖ Cardiology
- ❖ Diabetology
- ❖ Pain Management
- ❖ CNS
- ❖ Anti Infective
- ❖ Vitamins & Minerals
- ❖ Hematology
- ❖ Lung Cancer

ONCOLOGY PRODUCTS LAUNCHED

PAZOCAM™
Pazopanib Hydrochloride Tablets 200 mg / 400 mg

Capivo™
Capecitabine Tablets IP 150 / 500 mg

Lenvamed™
Lenvatinib Capsules 4 mg / 10 mg

ABTmed™
Abiraterone Tablets 250 mg

Raxitinib™
Axitinib Tablets 1 mg / 5 mg

Dasamed™
Dasatinib Tablets 20mg / 50 mg / 70 mg / 100mg

Temo-GBM™
Temozolomide Capsules IP 20 mg / 100 mg / 250 mg

ETBmed™
Erlotinib Tablets IP 100 mg / 150 mg

Ledomed™
Lenalidomide Capsules 10 mg / 15 mg / 25 mg

AB-Taxomed™
Paclitaxel (protein bound particles) for Injectable suspension 100 mg / vial

Fasvivo™
Fulvestrant Injection (250 mg/5 ml) PFS

Urea, Lactic Acid & Glycerin Cream

Radiamed™

Cream

रेडियामेड

PRODUCTS TO BE LAUNCHED IN CURRENT FINANCIAL YEAR

MEDIIMUSTINE™
Bendamustine Injection IP 100mg/vial

PEMETOMED™
Pemetrexed for Injection 100 / 500 mg/vial

Borzomed™
Borizomib Injection 2 mg / 2.5 mg / 3.5 mg per vial

AZACAMEN™
Azacitidine for Injection 100 mg/vial

Busmed™
Busulfan Injection 60 mg / 10ml Injection

AFMED™
Afatinib Tablets 20 mg / 30 mg / 40 mg

Imamed™
Imatinib Tablets IP 100 mg / 400 mg

State of Art – Manufacturing Facilities

Research & Development
Centre



General Formulation facility
Bhiwadi



State of Art – Manufacturing Facilities

General Formulation facility
Haridwar Unit-I



Oncology Formulation facility
Haridwar Unit-II





Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500 (30 Lines)

Fax: 011-26213081

E-mail: cs@medicamen.com

Website: www.medicamen.com